Miller on Oncology

Kathy D. Miller, MD, is associate director of clinical research at the Melvin and Bren Simon Cancer Center at Indiana University. Her research combines laboratory and clinical research in breast cancer. She is chair of the ECOG-ACRIN Breast Core Committee, where she works with academic scientists and community oncologists to develop trials that combine clinical and biologic endpoints yet remain feasible in nonacademic settings. In addition, she serves as principal investigator of the National Clinical Trials Network at Indiana University.

+ Add to Email Alerts

Unintended Consequences of the Alabama Anti-DEI Law Dr Kathy Miller discusses unintended consequences of the Alabama anti-DEI law.
Medscape Oncology, March 05, 2025
SABCS 2024 PATINA Trial Shifts Paradigm in HER2+/ER+ Breast Cancer Dr Kathy Miller discusses how the PATINA trial reshapes treatment strategies for HER2+/ER+ breast cancer patients.
Medscape Oncology, February 28, 2025
How Anti-DEI Laws May Undermine Clinical Trial Results Dr Kathy Miller discusses anti-DEI legislation and the implications for future research.
Medscape Oncology, January 13, 2025
SABCS 2024 Studies to Watch: San Antonio Breast Cancer Symposium Dr Kathy Miller discusses studies of interest at the upcoming San Antonio Breast Cancer Symposium.
Medscape Oncology, December 16, 2024
The Clinical Utility of ctDNA Testing: Not There Yet Dr Kathy Miller discusses the clinical utility of ctDNA testing.
Medscape Oncology, March 27, 2024
In Memoriam: Drs Worta McCaskill-Stevens and Edith Mitchell Dr Kathy Miller remembers two influential women in the breast cancer field, Dr Worta McCaskill-Stevens and Dr Edith Mitchell.
Medscape Oncology, March 14, 2024
PATHFINDER: Not Quite Hitting the Mark? Dr Kathy Miller discusses the potential mismatch between results and conclusions from the PATHFINDER study.
Medscape Oncology, March 04, 2024
Regional Nodal Radiation in Early Breast Cancer Dr Kathy Miller discusses the most recent results on regional nodal radiation from the Early Breast Cancer Trialists' Collaborative Group.
Medscape Oncology, February 27, 2024
Oxford Analyses: We Need to Ask About Data Availability Kathy Miller discusses the importance of collaboration, participation, and data availability for future Oxford analyses.
Medscape Oncology, February 16, 2024
Match Programs vs the NFL Draft: Where Would You End Up? Kathy D. Miller, MD, discusses the NFL draft and residency match programs.
Medscape Oncology, August 14, 2023
Considering the True Costs of Clinical Trials Kathy D. Miller, MD, discusses health equity and the true costs of clinical trials.
Medscape Oncology, August 08, 2023
FES PET for ER-Positive Breast Cancer: How Can It Help? Kathy D. Miller, MD, and Hannah M. Linden, MD, discuss the use of FES PET for patients with ER-positive breast cancer.
Medscape Oncology, July 18, 2023
NATALEE, PHERGain Show Promise in Breast Cancer at ASCO Kathy D. Miller, MD, discusses results from breast cancer trials presented at the 2023 ASCO annual meeting.
Medscape Oncology, June 15, 2023
Want to Thank Trial Participants? Provide Crossover Kathy D. Miller, MD, shares a final thought after attending the 2022 San Antonio Breast Cancer Symposium.
Medscape Oncology, January 10, 2023
SABCS 2022 ER+ Breast Cancer Data: SERDs, Pregnancy, and New Targets Kathy D. Miller, MD, and Kevin Kalinsky, MD, discuss recent studies important for treating patients with ER-positive disease.
Medscape Oncology, January 03, 2023
SABCS 2022 Deescalating DCIS: Experts Discuss New Data From SABCS Kathy D. Miller, MD, and Shelley Hwang, MD, MPH, discuss studies focusing on DCIS from the 2022 San Antonio Breast Cancer Conference.
Medscape Oncology, December 27, 2022
Covering for a Colleague: My Treatment Recommendation or Theirs? Dr Kathy Miller discusses an ethical issue she recently faced when covering for a colleague.
Medscape Oncology, December 14, 2022
ASCO 2022 'Real-World' Data: Watchword or Accurate Description? Dr Kathy Miller discusses real-world data and whether reports accurately include these data.
Medscape Oncology, December 07, 2022
ASCO 2022 'It's an ADC World': New Breast Cancer Data From ASCO 2022 Drs Kathy Miller and Harold Burstein discuss new breast cancer data presented at the recent annual meeting of the American Society of Clinical Oncology.
Medscape Oncology, July 05, 2022
What Explains 'Sobering' Variations in Breast Cancer Care? Kathy Miller discusses results from a recent study illustrating the impact of geography on breast cancer care.
Medscape Oncology, April 28, 2022
Managing a Loved One's Finances: 'Do You Have a Magic Book?' Kathy Miller discusses the importance of preparing financial information for loved ones to access in the case of medical emergencies.
Medscape Oncology, April 25, 2022
ASCO 2021 Real-World Breast Cancer Tx Fall Far Short of Trial Outcomes Dr Kathy Miller discusses a recent report highlighting the difference in outcomes among clinical trials and real-world settings.
Medscape Oncology, November 11, 2021
Adjuvant IO Fails in BRCA+ Breast Cancer Patient; Now What? Dr Kathy Miller discusses potential treatment options for patients with triple-negative breast cancer.
Medscape Oncology, October 01, 2021
We Need to Level With Our Patients About Tumor Sequencing A recent look at the real-world benefits of tumor sequencing suggests that it may be a mixed bag for patients, says Dr Kathy Miller.
Medscape Oncology, August 27, 2021
Looking for a Good Read? Two End-of-Summer Book Recommendations Dr Kathy Miller provides two end-of-summer science book club recommendations.
Medscape Oncology, August 26, 2021
ASCO 2021 For Residual TNBC Post-Chemo, Capecitabine Should Be Offered For high-risk patients with triple-negative breast cancer who have residual disease following neoadjuvant therapy, Dr Kathy Miller says we must accept capecitabine as the standard of care.
Medscape Oncology, June 15, 2021
ASCO 2021 Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer Dr Kathy Miller shares the 'biggest news in the breast cancer world' from ASCO, with presented data showing the benefit of olaparib in patients with high-risk, BRCA-mutated HER2-negative disease.
Medscape Oncology, June 11, 2021
ASCO 2021 ASCO 2021: Breast Cancer Sessions Not to Miss Dr Kathy Miller discusses anticipated highlights of ASCO 2021.
Medscape Oncology, June 02, 2021
The Power of Independent Data Monitoring Committees Is Diminishing Dr Kathy Miller sees the power of IDMCs eroding, and warns that this will lead to a loss of confidence in the safety and reliability of new treatments.
Medscape Oncology, May 05, 2021
Single-Cell Sequencing Upends Breast Cancer Assumptions This study turns previous assumptions about the genesis of breast cancers on its head, says Dr Kathy Miller.
Medscape Oncology, April 28, 2021
Margetuximab for HER2+ Metastatic Breast Cancer Falls Short With such a small improvement in progression-free survival, margetuximab is 'simply not enough' for advanced HER2+ breast cancer, says Dr Kathy Miller.
Medscape Oncology, January 07, 2021
CONTESSA: Oral Taxane Meets Primary Endpoint FDA is likely to approve this formulation, says Dr Kathy Miller.
Medscape Oncology, January 06, 2021
RxPONDER: Chemo 'No Longer a Mandate' for Some With Breast Cancer Dr Kathy Miller shares the impactful results of the RxPONDER trial presented at the San Antonio Breast Cancer Symposium.
Medscape Oncology, January 04, 2021
ESMO 2020 Opposing Trial Results on CDK Inhibitors Means Good Science The results of monarchE and PALLAS are creating more questions than answers. Dr Kathy Miller explains why that is a good thing.
Medscape Oncology, October 07, 2020
ESMO 2020 Innate Immune Response Produces 'Phenomenal' Breast Cancer Control A unique study illustrates the extraordinary power of the immune system to control cancer when it's able to recognize the tumor.
Medscape Oncology, October 01, 2020
ESMO 2020 For Immunotherapy in TNBC, Nab-paclitaxel Is a Must Why are results so different between IMpassion130 and IMpassion131? There is no clear answer, says Dr Kathy Miller.
Medscape Oncology, September 24, 2020
Surprising Results From the PALLAS Trial Dr Kathy Miller discusses the surprising -- and disappointing -- results from the PALLAS trial, which caught many off-guard by being announced via press release after the virtual ASCO meeting.
Medscape Oncology, July 01, 2020
In Breast Cancer, Is Chemobrain Really 'Endocrine Brain'? Dr Kathy Miller explores how new data from the TAILORx trial change our understanding of a common but -- to date -- poorly defined side effect.
Medscape Oncology, June 22, 2020
Three Practice-Informing Breast Cancer Trials From ASCO 2020 Dr Kathy Miller comments on three breast cancer trials presented at this year's virtual ASCO meeting and notes that even a negative trial can have a silver lining.
Medscape Oncology, June 18, 2020
ASCO Plenary Highlights Importance of Publicly Funded Research The question posited by the E2108 study, which is being presented at this year's ASCO annual meeting, may not have a financial incentive, but it is vital for clinical practice.
Medscape Oncology, May 29, 2020
Let's Not 'Waste' COVID-19: Opportunities for Improvement Dr Kathy Miller discusses beneficial changes that have resulted from the COVID-19 pandemic and implications for the future of medicine.
Medscape Oncology, May 07, 2020
De-escalation of Cancer Treatment: When Is Less Really More? 'We've gotten very comfortable overtreating people,' says Dr Kathy Miller. Listen in as she and Dr Eric Winer discuss the controversial concept of de-escalating therapy for breast cancer.
Medscape Oncology, February 05, 2020
As Home Genetic Tests Flood Market, Are Physicians Being Left Behind? Direct-to-consumer genetic testing has made it more accessible to patients. Drs Kathy Miller and Susan Domchek discuss the implications involved with this testing for patients and physicians.
Medscape Oncology, January 22, 2020
Three Questions Can Help Quantify Health Disparities Drs Kathy Miller and Samilia Obeng-Gyasi discuss research on whether health disparities affect outcomes in clinical trials, and how collecting certain patient information upfront can make a difference.
Medscape Oncology, January 14, 2020
Early ImmunoRx Results in TNBC 'Put Us in a Difficult Position' Major differences in the results of two separate studies with addition of immunotherapy in triple-negative breast cancer are making this space more complicated than clear, according to Dr Kathy Miller.
Medscape Oncology, January 14, 2020
'Huge Year' for HER2+ Breast Cancer: Incorporating New Treatments Drs Kathy Miller and Sara Hurvitz reflect on some of the trial results, including HER2CLIMB and DESTINY-Breast01, presented at this year's SABCS that may 'take your breath away.'
Medscape Oncology, December 27, 2019
Remembering Bernie: An Early Champion in Breast Cancer Dr Kathy Miller remembers Dr Bernard Fisher and his substantial contributions to the field of breast cancer.
Medscape Oncology, November 01, 2019
Is the 'Value' Movement Affecting Everyday Oncology Practice? 'It's finally starting to happen.' Drs Miller, Saltz, and Schwartzberg discuss how the concept of value is both changing and challenging the cancer care community.
Medscape Oncology, July 18, 2019
Breast Cancer at ASCO 2019: IO, CDK4/6i, and New Approvals Drs Miller and Burstein discuss advances presented at ASCO 2019 in immunotherapy, CDK4/6 inhibitors, and neoadjuvant TDM-1 therapies for breast cancer.
Medscape Oncology, June 07, 2019
'Pendulum Has Swung Too Far' in Opioid Limits for Cancer Pain Dr Kathy Miller discusses the impact of the opioid epidemic on patients with metastatic disease.
Medscape Oncology, April 25, 2019
Breast Cancer Genetic Testing Guidelines 'Simply Are Not Effective' Kathy Miller discusses current breast cancer genetic testing guidelines and considerations for more widespread genetic testing.
Medscape Oncology, April 18, 2019
Let's Put Breast Implant Lymphoma Risk in Context Dr Kathy Miller discusses the importance of placing risks in context, and questions the level of side-effect risk required for fully informed consent.
Medscape Oncology, April 09, 2019
Randomized Data (Finally) on Partial Breast Irradiation Drs Julia White and Kathy Miller discuss the informative and long-awaited results of the NSABP B-39/RTOG 0413 trial comparing whole vs partial breast irradiation.
Medscape Oncology, February 05, 2019
#MeToo Era Presents Complex Questions for Oncology Drs Kathy Miller and Reshma Jagsi discuss research findings and important issues related to sexual harassment and discrimination.
Medscape Oncology, January 29, 2019
Hudis on CancerLinQ: Goal Is Real-Time 'Accident Avoidance System' CancerLinQ is a 'huge, expensive, cumbersome, and complex project, but it's also fun and rewarding to make it happen.' Kathy Miller talks with ASCO CEO Cliff Hudis about this challenging project.
Medscape Oncology, January 22, 2019
Interpreting the 'Messy Early Days' of Immunotherapy in Breast Cancer Peter Schmid, the 'Most Popular Man in San Antonio,' discusses the long-awaited results of IMpassion130, the ground-breaking trial evaluating immunotherapy for metastatic triple-negative breast cancer.
Medscape Oncology, December 13, 2018
Kathy Miller on IMpassion130: New Standard? Not Yet New standard of care? Not so fast, says Kathy Miller.
Medscape Oncology, November 08, 2018
'No Excuse' for Undisclosed COI, but Perhaps a Simple Solution Kathy Miller offers a simple solution to a complex problem.
Medscape Oncology, October 09, 2018
Diagnosing Inflammatory Breast Cancer: Can We Get on the Same Page? 'I know it when I see it' is just not good enough, says Dr Kathy Miller.
Medscape Oncology, September 18, 2018
Are Oncology Pathways 'Achieving the Goals We Promised'? Dr Kathy Miller talks with Dr Robin Zon about ASCO's effort to assess clinical pathways programs, and whether pathways programs are transparent and evidence-based in their recommendations.
Medscape Oncology, July 05, 2018
Clinical Pathways: Many Potential Benefits but 'More Work to Do' Drs Miller and Zon discuss the current challenges associated with clinical pathways in oncology.
Medscape Oncology, June 20, 2018
TAILORx Provides 'Clear Answer' for ER+ Breast Cancer Lead investigator Joseph Sparano discusses the pivotal TAILORx trial presented at ASCO 2018. It's a 'great day for patients,' says Kathy Miller.
Medscape Oncology, June 13, 2018
Long-Awaited TAILORx Results 'Will Impact Your Practice' 'Do not miss' the results of TAILORx this year at ASCO 2018, says Dr Kathy Miller, because they will likely affect management of ER-positive breast cancer.
Medscape Oncology, May 30, 2018
'False Hope' Over Immunotherapy? The Media's Misguided Effects Dr Kathy Miller responds to a recent New York Times article documenting rare immunotherapy responses, which may lead to false hope among cancer patients and their families.
Medscape Oncology, March 05, 2018
'Cultural Change' in DCIS Some think it's time to change how we talk about DCIS and to consider de-escalation of therapy. Drs Kathy Miller and Shelley Hwang discuss these hot topics and the COMET study at SABCS 2017.
Medscape Oncology, January 17, 2018
Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers Evaluation of biomarkers after 5 years of standard therapy for hormone-positive breast cancer may help determine those at risk for recurrence and those who may need further endocrine therapy.
Medscape Oncology, January 17, 2018
Will Immunotherapy Be a PANACEA for Breast Cancer? Drs Kathy Miller and Sherene Loi discuss advances in immunotherapy for breast cancer, particularly in HER2-positive disease and TNBC.
Medscape Oncology, January 02, 2018
For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab.
Medscape Oncology, December 29, 2017
Does Breast Cancer Risk REACT to Celecoxib? Does this COX-2 inhibitor alter breast cancer risk? Dr Kathy Miller discusses the results of the REACT trial with its primary investigator, Dr Charles Coombes.
Medscape Oncology, December 27, 2017
Hot Topics (and Hot Chilis): SABCS 2017 Dr Kathy Miller highlights potential practice-changing studies that she is looking forward to at SABCS 2017.
Medscape Oncology, December 05, 2017
Two 'P' Words Top List of Hot Topics in Breast Cancer Dr Kathy Miller points to PARP inhibitors and pertuzumab as highpoints of the breast cancer program at the upcoming ASCO meeting, including the plenary presentation of the OlympiAD trial.
Medscape Oncology, May 26, 2017
How Physicians Influence Patient Choices The quality of information that physicians give patients affects their decisions, concludes Dr. Kathy Miller, who reports on a recent study in which a video helped patients to make end-of-life decisions.
Medscape Oncology, July 25, 2012

No Results